Clinical Trial Update: The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the effect of psilocybin on symptom severity and synaptic density in major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry | Conditions: Major Depressive Disorder, Depression | Phase 2 | Status: COMPLETED